Basgoz Nesli 4

4 · Allergan plc · Filed May 12, 2020

Form 4

Period: 2020-05-08

Director

Transactions

Disposition to Issuer
Ordinary Shares, par value $0.0001
2020-05-08−6,888.913→ 0 total
Disposition to Issuer
Stock Options
2020-05-08−2,790→ 0 total
Exercise: $90.22Exp: 2023-08-14→ Ordinary Shares (2,790 underlying)
Disposition to Issuer
Stock Options
2020-05-08−3,691→ 0 total
Exercise: $73.14Exp: 2022-08-22→ Ordinary Shares (3,691 underlying)
Disposition to Issuer
Stock Options
2020-05-08−2,619→ 0 total
Exercise: $70.79Exp: 2021-08-22→ Ordinary Shares (2,619 underlying)

Footnotes (3)

[F1]Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
[F2]Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
[F3]All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

Documents

1 file